ISU Abxis Co., Ltd. Logo

ISU Abxis Co., Ltd.

Developing antibody-based immunotherapies for oncology and rare diseases.

086890 | KO

Overview

Corporate Details

ISIN(s):
KR7086890001
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 대왕판교로712번길 22, 씨동 5층 (삼평동, 글로벌알앤디센터), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ISU Abxis Co., Ltd. is a biopharmaceutical company that pioneers the discovery and development of engineered antibody-based immunotherapies. The company leverages its advanced antibody technology platform to address significant unmet medical needs in oncology and rare diseases. Its pipeline includes therapeutic candidates such as ISU104 for solid tumors and Fabagal, a treatment for Fabry disease. Founded in 2001, the company is dedicated to developing novel bio-therapeutics to enhance the quality of life for patients with difficult-to-treat conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-08-22 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.0 MB
2025-08-11 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-08-08 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.3 KB
2025-07-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.4 KB
2025-07-14 00:00
Share Issue/Capital Change
전환청구권행사
Korean 9.4 KB
2025-07-14 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.1 KB
2025-07-11 00:00
Share Issue/Capital Change
전환청구권행사
Korean 14.0 KB
2025-07-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-07-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 99.4 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-06-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 107.4 KB
2025-06-24 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-06-19 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 18.0 KB

Automate Your Workflow. Get a real-time feed of all ISU Abxis Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ISU Abxis Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ISU Abxis Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

C4 Therapeutics, Inc. Logo
Developing protein degrader medicines to treat cancer and other serious diseases.
United States of America
CCCC
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
United States of America
CABA
Cadrenal Therapeutics, Inc. Logo
Developing novel anticoagulant therapies for high-risk cardiovascular patients.
United States of America
CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.
United States of America
CALC
Calidi Biotherapeutics, Inc. Logo
Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.
United States of America
CLDI
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden
CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea
402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom
CNSL
Camp4 Therapeutics Corp Logo
Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.
United States of America
CAMP
Camurus Logo
Develops long-acting medicines for severe chronic diseases using advanced drug delivery.
Sweden
CAMX

Talk to a Data Expert

Have a question? We'll get back to you promptly.